Moreover, Ariës et al. found Trametinib could restore prednisolone sensitivity in RAS-mutant BCP-ALL patient samples, whereas Rambal et al. showed that MEK activation reduces dexamethasone sensitivity, and the MEK inhibitor PD183452 enhanced dexamethasone responses in ALL cells in a BIM-dependent manner [24, 25]. Here, MAP2K7 is linked to acute lymphoblastic leukemia.